Time：2025-11-11
Medtide Inc. ("theCompany"; Stock Code: 3880) has been officially named a 2025"Hangzhou Headquarters Enterprise", in recognition of its leadingcomprehensive strength in peptides and oligonucleotides. The honor underscoresthe company’s pivotal role in headquarters economy and its benchmark status inthe global peptide and oligonucleotide drug R&D, production and servicesector.
About Medtide Inc.
Medtide Inc. is a peptide-focused contract research,development, and manufacturing organization (CRDMO), offering full-cycleservices ranging from early-stage discovery, pre-clinical research and clinicaldevelopment to commercial-stage production. The company is headquartered inHangzhou, China, and has commercial production bases and offices in both Chinaand the United States. We have been deeply involved in the peptide field forover 20 years. Today, we have become a CRDMO with global operations andcomprehensive service capabilities.
Medtide Inc. provides (i) contract research organization (CRO) services,namely peptide new chemical entity (NCE) discovery synthesis; and (ii) contractdevelopment and manufacturing organization (CDMO) services, namely peptidechemistry, manufacturing and controls (CMC) development and commercialmanufacturing. We have established global operations, with projects coveringover 50 countries, including major markets such as China, the United States,Japan, Europe, South Korea, and Australia. We provide our 1000+ customers withpeptide drug development, production, and CMC documentation and filing supportservices that meet regulatory requirements in major markets worldwide.
As a trusted and sustainable enterprise, Medtide Inc. has establishedlong-term partnerships with many customers. Through close collaboration, weassist customers in bringing drugs that profoundly impact human health to themarket, focusing on patients and committed to improving their lives, thuspromoting the development of the human health industry.
